ECSP099773A - Moduladores de gamma secretasa - Google Patents

Moduladores de gamma secretasa

Info

Publication number
ECSP099773A
ECSP099773A EC2009009773A ECSP099773A ECSP099773A EC SP099773 A ECSP099773 A EC SP099773A EC 2009009773 A EC2009009773 A EC 2009009773A EC SP099773 A ECSP099773 A EC SP099773A EC SP099773 A ECSP099773 A EC SP099773A
Authority
EC
Ecuador
Prior art keywords
compounds
methods
modulators
gamma
secretasa
Prior art date
Application number
EC2009009773A
Other languages
English (en)
Inventor
Zhaoning Zhu
Zhong-Yue Sun
William J Greenlee
Xianhai Huang
Ruo Xu
Xiaohong Zhu
Gioconda Gallo
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ECSP099773A publication Critical patent/ECSP099773A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

En sus muchas realizaciones, la presente invención provee una clase novedosa de compuestos heterocíclicos como moduladores de gamma secretasa, métodos para preparar ese tipo de compuestos, composiciones farmacéuticas que contienen uno o más compuestos de ese tipo, métodos para preparar formulaciones farmacéuticas que comprenden uno o más compuestos de ese tipo, y métodos de tratamiento, prevención, inhibición o mejora de una o más enfermedades asociadas con el sistema nervioso central que utilizan dichos compuestos o composiciones farmacéuticas.
EC2009009773A 2007-06-01 2009-11-30 Moduladores de gamma secretasa ECSP099773A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94139607P 2007-06-01 2007-06-01

Publications (1)

Publication Number Publication Date
ECSP099773A true ECSP099773A (es) 2009-12-28

Family

ID=40130388

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009773A ECSP099773A (es) 2007-06-01 2009-11-30 Moduladores de gamma secretasa

Country Status (18)

Country Link
US (1) US8580956B2 (es)
EP (1) EP2164852A2 (es)
JP (1) JP2010529014A (es)
KR (1) KR20100021633A (es)
CN (1) CN101932578A (es)
AR (1) AR066151A1 (es)
AU (1) AU2008263206A1 (es)
BR (1) BRPI0812491A2 (es)
CA (1) CA2689930A1 (es)
CL (1) CL2008001559A1 (es)
CO (1) CO6241125A2 (es)
EC (1) ECSP099773A (es)
IL (1) IL202316A0 (es)
MX (1) MX2009013130A (es)
PE (1) PE20090319A1 (es)
RU (1) RU2009148865A (es)
TW (1) TW200904422A (es)
WO (1) WO2008153792A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2152695A2 (en) 2007-06-01 2010-02-17 Schering Corporation Gamma secretase modulators
CA2742317A1 (en) * 2008-11-06 2010-05-14 Schering Corporation Gamma secretase modulators
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
TN2017000342A1 (en) 2015-02-03 2019-01-16 Pfizer Novel cyclopropabenzofuranyl pyridopyrazinediones
MX2020008126A (es) * 2018-02-01 2020-09-18 Japan Tobacco Inc Compuesto de amida heterociclica nitrogenada y su uso para fines medicos.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2188584T3 (es) * 1991-03-28 2003-07-01 Eisai Co Ltd Derivados heterociclicos de amina.
WO2004071431A2 (en) 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
EP1628666B1 (en) 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
CA2532207A1 (en) 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
US20070293538A1 (en) 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
CA2567223A1 (en) 2004-05-19 2005-11-24 Boehringer Ingelheim International Gmbh Treatment of diseases associated with altered level of amyloid beta peptides
BRPI0511504A (pt) 2004-05-26 2008-01-22 Eisai R&D Man Co Ltd composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
EP1650183A1 (en) 2004-10-21 2006-04-26 Cellzome Ag (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy
MY144960A (en) * 2005-11-24 2011-11-30 Eisai R&D Man Co Ltd Morpholine type cinnamide compound
US20070117839A1 (en) 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound

Also Published As

Publication number Publication date
IL202316A0 (en) 2010-06-30
AR066151A1 (es) 2009-07-29
RU2009148865A (ru) 2011-07-20
WO2008153792A3 (en) 2009-05-07
AU2008263206A1 (en) 2008-12-18
PE20090319A1 (es) 2009-03-27
AU2008263206A2 (en) 2010-01-21
JP2010529014A (ja) 2010-08-26
KR20100021633A (ko) 2010-02-25
EP2164852A2 (en) 2010-03-24
CA2689930A1 (en) 2008-12-18
CL2008001559A1 (es) 2008-12-05
BRPI0812491A2 (pt) 2014-12-02
TW200904422A (en) 2009-02-01
US8580956B2 (en) 2013-11-12
CO6241125A2 (es) 2011-01-20
CN101932578A (zh) 2010-12-29
MX2009013130A (es) 2010-01-15
US20100255005A1 (en) 2010-10-07
WO2008153792A2 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
ECSP099720A (es) Moduladores de gamma-secretasa
ECSP099776A (es) Moduladores de la gamma secretasa
MX2010001506A (es) Moduladores de gamma secretasa.
CL2016001364A1 (es) Moduladores de ror gamma (rory)
CL2011000043A1 (es) Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central.
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
CL2012001955A1 (es) Compuestos derivados biciclicos de triazol sustituidos, moduladores de gamma secretasa; composicion farmaceutica que los comprende; utiles en el tratamiento o la prevencion de enfermedad de alzheimer, demencia, demencia asociada con la enfermedad de parkinson, entre otras.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
GT201200220A (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo
CL2013000380A1 (es) Compuestos heterociclicos derivados de [1,2,4] tiadiazina, moduladores positivos del receptor de ampa; medicamento que los contiene; y su uso para la prevencion o el tratamiento de depresion, enfermedad de alzheimer, esquizofrenia o trastorno de hiperactividad de deficit de atencion.
CL2011003350A1 (es) Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
CO6470899A2 (es) 2,4-diaminopirimidinas para el tratamiento de enfermedades caracterizadas por proliferación celular excesiva o normal
CL2008002876A1 (es) Compuestos derivados de heterociclo sustituidos, moduladores de gamma-secretasa; composicion farmaceutica que los comprende; uso en el tratamiento de enfermedades neurodegenerativas como alzheimer o sindrome de down.
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
AR061637A1 (es) Composiciones y metodos de tratamiento de trastornos del snc
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
CO7151509A2 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
CL2008001990A1 (es) Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer.
BR112015006727A8 (pt) uso de uma composição farmacêutica
CL2011000168A1 (es) Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer.
MX368635B (es) Compuestos tricíclicos de piperidina.
CL2009001282A1 (es) Compuestos derivados de pirrolidin amidas sustituidas, moduladores del receptor de histamina h3; composicion farmaceutica que los contiene; y su uso para el tratamiento de enfermedades tales como demencia, alzheimer, disfuncion cognitiva, trastorno de la memoria, trastorno de aprendizaje, deficit atencional, entre otras.